AC Immune SA (ACIU) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

ACIU Stock Forecast

AC Immune SA stock forecast is as follows: an average price target of $9.00 (represents a 175.23% upside from ACIU’s last price of $3.27) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ACIU Price Target

The average price target for AC Immune SA (ACIU) is $9.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $8.00. This represents a potential 175.23% upside from ACIU's last price of $3.27.

ACIU Analyst Ratings

Buy

According to 3 Wall Street analysts, AC Immune SA's rating consensus is 'Buy'. The analyst rating breakdown for ACIU stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

AC Immune SA Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 30, 2024	Thomas Shrader	BTIG	$8.00	$3.97	101.51%	144.65%
Jul 11, 2022	-	Leerink Partners	$10.00	$3.35	198.51%	205.81%

Row per page

Go to

The latest AC Immune SA stock forecast, released on May 30, 2024 by Thomas Shrader from BTIG, set a price target of $8.00, which represents a 101.51% increase from the stock price at the time of the forecast ($3.97), and a 144.65% increase from ACIU last price ($3.27).

AC Immune SA Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$8.00
Last Closing Price	$3.27	$3.27	$3.27
Upside/Downside	-100.00%	-100.00%	144.65%

In the current month, the average price target of AC Immune SA stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AC Immune SA's last price of $3.27. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 18, 2024	H.C. Wainwright	Buy	Buy	Hold
May 30, 2024	BTIG	-	Buy	Initialise
Jul 11, 2022	SVB Leerink	Outperform	Outperform	Hold

Row per page

Go to

AC Immune SA's last stock rating was published by H.C. Wainwright on Sep 18, 2024. The company gave ACIU a "Buy" rating, the same as its previous rate.

AC Immune SA Financial Forecast

AC Immune SA Revenue Forecast

	Dec 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Dec 22	Sep 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Sep 16
Revenue	-	-	-	-	-	-	-	-	$1.00K	$3.93M	-	-	-	-	-	$944.00K	$1.12M	$1.28M	$12.41M	$1.06M	$33.41M	$1.51M	$75.04M	$1.46M	$2.01M	$1.33M
Avg Forecast	$180.99M	$1.17M	$7.20M	$90.89M	$5.34M	$15.29M	$50.07M	$2.50M	$1.60M	$349.15K	$350.82K	$28.15M	$631.68K	$1.77M	$3.41M	$769.57K	$425.00K	$199.47K	$12.82M	$1.77M	$31.01M	$1.17M	$98.07M	$1.53M	$1.89M	$1.18M
High Forecast	$360.07M	$2.32M	$14.33M	$180.83M	$10.62M	$16.56M	$99.61M	$4.98M	$3.18M	$349.15K	$350.82K	$28.15M	$631.68K	$1.77M	$3.41M	$769.57K	$425.00K	$199.47K	$12.82M	$1.77M	$31.01M	$1.17M	$98.07M	$1.84M	$2.27M	$1.42M
Low Forecast	$61.92M	$398.85K	$2.46M	$31.10M	$1.83M	$14.02M	$17.13M	$855.63K	$547.17K	$349.15K	$350.82K	$28.15M	$631.68K	$1.77M	$3.41M	$769.57K	$425.00K	$199.47K	$12.82M	$1.77M	$31.01M	$1.17M	$98.07M	$1.23M	$1.51M	$945.78K
# Analysts	1	3	2	1	1	2	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	7	9
Surprise %	-	-	-	-	-	-	-	-	0.00%	11.27%	-	-	-	-	-	1.23%	2.64%	6.41%	0.97%	0.60%	1.08%	1.29%	0.77%	0.95%	1.06%	1.13%

AC Immune SA's average Quarter revenue forecast for Jun 23 based on 1 analysts is $2.50M, with a low forecast of $855.63K, and a high forecast of $4.98M. ACIU's average Quarter revenue forecast represents a 250007.40% increase compared to the company's last Quarter revenue of $1.00K (Dec 22).

AC Immune SA EBITDA Forecast

	Dec 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Dec 22	Sep 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Sep 16
# Analysts	1	3	2	1	1	2	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	7	9
EBITDA	-	-	-	-	-	-	-	-	$-18.03M	$-12.87M	$-18.23M	$-20.47M	$-15.10M	$-18.27M	$-16.16M	$-18.95M	$-18.45M	$-15.21M	$-7.16M	$-18.77M	$18.73M	$-16.00M	$65.06M	$-11.40M	$-7.72M	$-7.98M
Avg Forecast	$-57.88M	$-372.81K	$-2.30M	$-29.07M	$-1.71M	$-4.89M	$-16.01M	$-799.78K	$-511.45K	$-110.41K	$-17.40M	$-8.90M	$-199.76K	$-560.79K	$-16.70M	$-243.37K	$-134.40K	$-63.08K	$-8.69M	$-558.91K	$-9.81M	$-370.21K	$81.20M	$-11.95M	$-7.24M	$-6.98M
High Forecast	$-19.80M	$-127.54K	$-788.00K	$-9.94M	$-583.92K	$-4.48M	$-5.48M	$-273.61K	$-174.97K	$-110.41K	$-13.92M	$-8.90M	$-199.76K	$-560.79K	$-13.36M	$-243.37K	$-134.40K	$-63.08K	$-6.95M	$-558.91K	$-9.81M	$-370.21K	$97.44M	$-9.56M	$-5.79M	$-5.59M
Low Forecast	$-115.14M	$-741.70K	$-4.58M	$-57.83M	$-3.40M	$-5.30M	$-31.85M	$-1.59M	$-1.02M	$-110.41K	$-20.88M	$-8.90M	$-199.76K	$-560.79K	$-20.04M	$-243.37K	$-134.40K	$-63.08K	$-10.43M	$-558.91K	$-9.81M	$-370.21K	$64.96M	$-14.34M	$-8.69M	$-8.38M
Surprise %	-	-	-	-	-	-	-	-	35.26%	116.59%	1.05%	2.30%	75.59%	32.59%	0.97%	77.87%	137.28%	241.13%	0.82%	33.58%	-1.91%	43.22%	0.80%	0.95%	1.07%	1.14%

9 analysts predict ACIU's average Quarter EBITDA for Dec 19 to be $-558.91K, with a high of $-558.91K and a low of $-558.91K. This is -102.98% lower than AC Immune SA's previous annual EBITDA (Sep 19) of $18.73M.

AC Immune SA Net Income Forecast

	Dec 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Dec 22	Sep 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Sep 16
# Analysts	1	3	2	1	1	2	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	7	9
Net Income	-	-	-	-	-	-	-	-	$-18.75M	$-13.52M	$-18.85M	$-21.28M	$-15.92M	$-19.07M	$-16.73M	$-19.50M	$-18.99M	$-15.74M	$-7.69M	$-19.45M	$18.21M	$-16.90M	$63.57M	$-11.61M	$-9.46M	$-9.10M
Avg Forecast	-	$-17.94M	$-13.66M	$47.98M	$-13.66M	$-9.77M	$3.05M	$-19.63M	$-24.84M	$-22.84M	$-17.99M	$9.97M	$-26.90M	$-20.82M	$-16.73M	$-24.80M	$-24.54M	$-29.02M	$-9.34M	$-22.14M	$17.12M	$-22.01M	$79.34M	$-12.17M	$-8.86M	$-7.96M
High Forecast	-	$-16.31M	$-1.98M	$48.56M	$-1.98M	$-2.79M	$3.08M	$-2.84M	$-3.60M	$-22.84M	$-14.39M	$9.97M	$-26.90M	$-20.82M	$-13.39M	$-24.80M	$-24.54M	$-29.02M	$-7.47M	$-22.14M	$17.12M	$-22.01M	$95.20M	$-9.73M	$-7.09M	$-6.37M
Low Forecast	-	$-18.76M	$-31.23M	$47.40M	$-31.23M	$-16.74M	$3.02M	$-44.88M	$-56.80M	$-22.84M	$-21.59M	$9.97M	$-26.90M	$-20.82M	$-20.08M	$-24.80M	$-24.54M	$-29.02M	$-11.20M	$-22.14M	$17.12M	$-22.01M	$63.47M	$-14.60M	$-10.64M	$-9.56M
Surprise %	-	-	-	-	-	-	-	-	0.75%	0.59%	1.05%	-2.13%	0.59%	0.92%	1.00%	0.79%	0.77%	0.54%	0.82%	0.88%	1.06%	0.77%	0.80%	0.95%	1.07%	1.14%

AC Immune SA's average Quarter net income forecast for Dec 19 is $-22.14M, with a range of $-22.14M to $-22.14M. ACIU's average Quarter net income forecast represents a -221.54% decrease compared to the company's last Quarter net income of $18.21M (Sep 19).

AC Immune SA SG&A Forecast

	Dec 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Dec 22	Sep 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Sep 16
# Analysts	1	3	2	1	1	2	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	7	9
SG&A	-	-	-	-	-	-	-	-	$-2.25M	$3.27M	$4.17M	$-4.11M	$5.42M	$5.24M	$4.34M	$-2.47M	$4.89M	$4.16M	$4.50M	$-1.41M	$3.96M	$3.58M	$3.29M	$2.71M	$2.39M	$1.71M
Avg Forecast	$236.38M	$1.52M	$9.41M	$118.71M	$6.97M	$19.97M	$65.39M	$3.27M	$2.09M	$456.01K	$458.19K	$36.77M	$825.01K	$2.32M	$4.46M	$1.01M	$555.07K	$260.51K	$5.47M	$2.31M	$40.50M	$1.53M	$4.11M	$2.00M	$2.47M	$1.54M
High Forecast	$470.27M	$3.03M	$18.72M	$236.18M	$13.87M	$21.63M	$130.09M	$6.50M	$4.16M	$456.01K	$458.19K	$36.77M	$825.01K	$2.32M	$4.46M	$1.01M	$555.07K	$260.51K	$6.56M	$2.31M	$40.50M	$1.53M	$4.93M	$2.40M	$2.96M	$1.85M
Low Forecast	$80.87M	$520.92K	$3.22M	$40.61M	$2.38M	$18.31M	$22.37M	$1.12M	$714.63K	$456.01K	$458.19K	$36.77M	$825.01K	$2.32M	$4.46M	$1.01M	$555.07K	$260.51K	$4.38M	$2.31M	$40.50M	$1.53M	$3.29M	$1.60M	$1.98M	$1.24M
Surprise %	-	-	-	-	-	-	-	-	-1.08%	7.18%	9.09%	-0.11%	6.57%	2.26%	0.97%	-2.45%	8.81%	15.95%	0.82%	-0.61%	0.10%	2.34%	0.80%	1.35%	0.97%	1.11%

AC Immune SA's average Quarter SG&A projection for Dec 22 is $2.09M, based on 1 Wall Street analysts, with a range of $714.63K to $4.16M. The forecast indicates a -36.20% fall compared to ACIU last annual SG&A of $3.27M (Sep 22).

AC Immune SA EPS Forecast

	Dec 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Dec 22	Sep 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Sep 16
# Analysts	1	3	2	1	1	2	1	1	1	1	1	1	1	1	1	10	10	10	10	9	9	9	9	20	7	9
EPS	-	-	-	-	-	-	-	-	$-0.22	$-0.16	$-0.23	$-0.29	$-0.22	$-0.26	$-0.23	$-0.27	$-0.26	$-0.22	$-0.11	$-0.27	$0.25	$-0.24	$0.94	$-0.20	$-0.17	$-0.18
Avg Forecast	-	$-0.18	$-0.14	$0.48	$-0.14	$-0.10	$0.03	$-0.19	$-0.25	$-0.23	$-0.22	$0.10	$-0.27	$-0.21	$-0.23	$-0.25	$-0.25	$-0.29	$-0.08	$-0.22	$0.17	$-0.22	$1.21	$-0.21	$-0.15	$-0.14
High Forecast	-	$-0.16	$-0.02	$0.48	$-0.02	$-0.03	$0.03	$-0.03	$-0.04	$-0.23	$-0.22	$0.10	$-0.27	$-0.21	$-0.23	$-0.25	$-0.25	$-0.29	$-0.08	$-0.22	$0.17	$-0.22	$1.21	$-0.17	$-0.12	$-0.11
Low Forecast	-	$-0.19	$-0.31	$0.47	$-0.31	$-0.17	$0.03	$-0.44	$-0.56	$-0.23	$-0.22	$0.10	$-0.27	$-0.21	$-0.23	$-0.25	$-0.25	$-0.29	$-0.08	$-0.22	$0.17	$-0.22	$1.21	$-0.25	$-0.18	$-0.16
Surprise %	-	-	-	-	-	-	-	-	0.89%	0.70%	1.04%	-2.90%	0.81%	1.24%	1.00%	1.08%	1.05%	0.75%	1.41%	1.22%	1.45%	1.09%	0.78%	0.95%	1.13%	1.33%

According to 9 Wall Street analysts, AC Immune SA's projected average Quarter EPS for Dec 19 is $-0.22, with a low estimate of $-0.22 and a high estimate of $-0.22. This represents a -188.95% decrease compared to ACIU previous annual EPS of $0.25 (Sep 19).

AC Immune SA Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BCEL	Atreca	$0.09	$4.00	4344.44%	Buy
IVVD	Invivyd	$0.77	$9.50	1133.77%	Buy
PMVP	PMV Pharmaceuticals	$1.59	$18.00	1032.08%	Buy
ANTX	AN2 Therapeutics	$1.06	$8.75	725.47%	Buy
PEPG	PepGen	$4.47	$29.50	559.96%	Buy
BDTX	Black Diamond Therapeutics	$2.55	$14.75	478.43%	Buy
AVTE	Aerovate Therapeutics	$2.67	$13.00	386.89%	Hold
FDMT	4D Molecular Therapeutics	$8.67	$41.00	372.90%	Buy
OPT	Opthea	$3.26	$14.00	329.45%	Buy
ANEB	Anebulo Pharmaceuticals	$1.52	$6.00	294.74%	Buy
ACRV	Acrivon Therapeutics	$6.38	$21.83	242.16%	Buy
RGNX	REGENXBIO	$9.56	$32.00	234.73%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
ACIU	AC Immune SA	$3.27	$9.00	175.23%	Buy
STOK	Stoke Therapeutics	$11.61	$30.60	163.57%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
PHVS	Pharvaris	$20.51	$39.67	93.42%	Buy
ABEO	Abeona Therapeutics	$5.89	$6.00	1.87%	Buy
EFTR	eFFECTOR Therapeutics	-	$5.50	-	Buy

ACIU Forecast FAQ

Is AC Immune SA a good buy?

Yes, according to 3 Wall Street analysts, AC Immune SA (ACIU) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ACIU's total ratings.

What is ACIU's price target?

AC Immune SA (ACIU) average price target is $9 with a range of $8 to $10, implying a 175.23% from its last price of $3.27. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AC Immune SA stock go up soon?

According to Wall Street analysts' prediction for ACIU stock, the company can go up by 175.23% (from the last price of $3.27 to the average price target of $9), up by 205.81% based on the highest stock price target, and up by 144.65% based on the lowest stock price target.

Can AC Immune SA stock reach $5?

ACIU's average twelve months analyst stock price target of $9 supports the claim that AC Immune SA can reach $5 in the near future.

What are AC Immune SA's analysts' financial forecasts?

AC Immune SA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $104.6M (high $208.1M, low $35.78M), average EBITDA is $-33.449M (high $-11.443M, low $-66.545M), average net income is $2.72M (high $28.29M, low $-33.819M), average SG&A $136.61M (high $271.79M, low $46.74M), and average EPS is $0.0269 (high $0.281, low $-0.335). ACIU's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $180.99M (high $360.07M, low $61.92M), average EBITDA is $-57.875M (high $-19.799M, low $-115M), average net income is $0 (high $0, low $0), average SG&A $236.38M (high $470.27M, low $80.87M), and average EPS is $0 (high $0, low $0).

Did the ACIU's actual financial results beat the analysts' financial forecasts?

Based on AC Immune SA's last annual report (Dec 2022), the company's revenue was $3.94M, beating the average analysts forecast of $2.3M by 71.13%. Apple's EBITDA was $-70.778M, beating the average prediction of $-18.023M by 292.70%. The company's net income was $-70.753M, beating the average estimation of $-65.673M by 7.74%. Apple's SG&A was $15.79M, beating the average forecast of $3M by 425.75%. Lastly, the company's EPS was $-0.85, beating the average prediction of $-0.698 by 21.82%. In terms of the last quarterly report (Dec 2022), AC Immune SA's revenue was $1K, missing the average analysts' forecast of $1.6M by -99.94%. The company's EBITDA was $-18.034M, beating the average prediction of $-511K by 3426.06%. AC Immune SA's net income was $-18.749M, missing the average estimation of $-24.842M by -24.53%. The company's SG&A was $-2.246M, missing the average forecast of $2.09M by -207.52%. Lastly, the company's EPS was $-0.22, missing the average prediction of $-0.246 by -10.68%